Related Experiment Video
Updated: Dec 22, 2025
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
Targeting T cell activation in immuno-oncology
S D Saibil1,2, P S Ohashi1,3
1Princess Margaret Cancer Centre, University of Toronto, Toronto, ON.
Abstract:
The years since 2009 have seen tremendous progress in unlocking the curative potential of the immune system for the treatment of cancer. Much of that revolution in immuno-oncology has been fueled by the clinical success of immune checkpoint inhibitors, particularly those targeting the PD-1 axis. Unfortunately, many patients still fail to benefit from checkpoint blockade or other immunotherapies. An inability to fully activate antitumour T cells contributes in part to the failure of those therapies. Here, we review the basic biology of T cell activation, with particular emphasis on the essential role of the dendritic cell and the innate immune system in T cell activation. The current understanding of the multiple factors that govern T cell activation and how they impinge on tumour immunotherapy are also discussed. Lastly, treatment strategies to potentially overcome barriers to T cell activation and to enhance the efficacy of immunotherapy are addressed.
Insights
Immuno-oncology advances, like PD-1 inhibitors, show promise but many patients don't respond. Improving T cell activation is key to enhancing cancer immunotherapy effectiveness.
Area of Science:
- Immunology
- Oncology
- Cancer Research
Background:
- Significant advancements in cancer treatment have been achieved through immuno-oncology since 2009.
- Immune checkpoint inhibitors, particularly targeting the PD-1 axis, have driven this revolution.
- However, a substantial number of patients do not respond to current immunotherapies.
Purpose of the Study:
- To review the fundamental biology of T cell activation.
- To emphasize the critical role of dendritic cells and the innate immune system in initiating T cell responses.
- To discuss factors influencing T cell activation and their impact on cancer immunotherapy.
Main Methods:
- Literature review of T cell activation pathways.
- Analysis of the interplay between innate immunity, dendritic cells, and T cell responses.
- Examination of factors limiting T cell activation in the tumor microenvironment.
Main Results:
- T cell activation is a complex process involving dendritic cells and innate immunity.
- Multiple factors can impede effective T cell activation against tumors.
- Current understanding highlights barriers to successful immunotherapy.
Conclusions:
- Overcoming barriers to T cell activation is crucial for improving immunotherapy outcomes.
- Strategies to enhance T cell activation may increase patient response rates.
- Further research into T cell activation pathways can optimize cancer treatment.
Related Concept Videos
01:27Tumor Immunotherapy
01:22T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:17The Tumor Microenvironment
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...